您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Alamandine
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Alamandine
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Alamandine图片
CAS NO:1176306-10-7
包装与价格:
包装价格(元)
5mg电议
10mg电议
50mg电议

产品介绍
Alamandine 是一种血管活性肽,是肾素-血管紧张素系统 (RAS) 的成员,还是一种 G 蛋白偶联受体 MrgD 的内源性配体。Alamandine 可通过抗高血压作用来保护肾脏和心脏。
生物活性

Alamandine, a member of the renin-angiotensin system (RAS), a vasoactive peptide, is an endogenous ligand of the G protein-coupled receptor MrgD. Alamandine targets to protect the kidney and heart through anti-hypertensive actions[1][2].

体外研究
(In Vitro)

Alamandine is generated by catalysis of Ang A via ACE2 or directly from Angiotensin 1-7 (Ang-(1-7)). Derived from angiotensin II (Ang II) by Ang II-converting enzyme 2 (ACE2), it shows vasodilating (thus protective) properties. Ang (1-7) can be decarboxylated to a peptide called Alamandine. Alamandine is also an endogenous peptide identified in human blood[1].
Alamandine elevates cAMP concentration in primary endothelial and mesangial cells, also suggesting Gs coupling[2].
Alamandine decreases secretion, expression, and blood levels of leptin. Alamandine induced expression of iNOS and plasminogen activator inhibitor-1 (PAI-1) in adipose tissue and isolated adipocytes[2].

体内研究
(In Vivo)

Alamandine (0.15 μL/h; administered by mini-osmotic pumps; for 6 weeks) treatment ameliorates hypertension and impaires left ventricle (LV) function in SHRs. Also decreases the mass gains of heart and lung in SHRs, suppresses cardiomyocyte cross-sectional area expansion, and inhibits the mRNA levels of atrial natriuretic peptide and brain natriuretic peptide[3].

Animal Model:Male spontaneously hypertensive rats (SHRs, 50-week-old)[3]
Dosage:0.15 μL/h (~50 μg/kg/day)
Administration:Administered by mini-osmotic pumps; for 6 weeks
Result:Attenuated hypertension, alleviated cardiac hypertrophy, and improved LV function.
分子量

855.00

性状

Solid

Formula

C40H62N12O9

CAS 号

1176306-10-7

Sequence

Ala-Arg-Val-Tyr-Ile-His-Pro

Sequence Shortening

ARVYIHP

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder-80°C2 years
-20°C1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro: 

H2O : 25 mg/mL(29.24 mM;Need ultrasonic)

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM1.1696 mL5.8480 mL11.6959 mL
5 mM0.2339 mL1.1696 mL2.3392 mL
10 mM0.1170 mL0.5848 mL1.1696 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: PBS

    Solubility: 25 mg/mL (29.24 mM); Clear solution; Need ultrasonic and warming

*以上所有助溶剂都可在本网站选购。